GLYATL2: A Potential Drug Target and Biomarker for Fatty Acid Oxidation and Disease

Target Name: GLYATL2

NCBI ID: G219970

GLYATL2

GLYATL2: A Potential Drug Target and Biomarker for Fatty Acid Oxidation and Disease

Fatty acid oxidation is a critical process for maintaining energy homeostasis and regulating various physiological functions in the body. N-acyltransferase-like protein 2 (glycine N-acyltransferase-like protein 2, GLYATL2) is a protein that has been identified as a potential drug target and biomarker for various diseases, including obesity, diabetes, and fatty liver disease.

GLYATL2 is a member of the Glycine N-acyltransferase family, which is involved in the transfer of acyl groups from low-energy molecules to high-energy molecules. The GLYATL2 gene was discovered in 2007 and has been expressed in various tissues and cell types, including liver, muscle, and heart.

GLYATL2 has been shown to play a key role in fatty acid oxidation and homeostasis. It is expressed in the liver and has been shown to be involved in the metabolism of fatty acids, including acyl-CoA, a key intermediate in the citric acid cycle. GLYATL2 has been shown to promote the oxidation of acyl-CoA to CoA and to enhance the rate of fatty acid oxidation in the liver.

In addition to its role in fatty acid oxidation, GLYATL2 has also been shown to be involved in various signaling pathways that regulate cellular processes, including inflammation, cell survival, and metabolism. GLYATL2 has been shown to be involved in the regulation of inflammation by suppressing the production of pro-inflammatory cytokines and promoting the production of anti-inflammatory cytokines. It has also been shown to be involved in cell survival and metabolism by regulating cell proliferation and lifespan.

GLYATL2 has also been shown to be a potential biomarker for various diseases, including obesity, diabetes, and fatty liver disease. Obesity is a condition characterized by excess body weight and is a major risk factor for a range of metabolic and cardiovascular diseases, including diabetes and fatty liver disease. GLYATL2 has been shown to be involved in the regulation of body weight and metabolism by promoting the oxidation of fatty acids and suppressing the production of pro-inflammatory cytokines. Diabetes is a condition characterized by high blood sugar levels and is a major risk factor for a range of diseases, including cardiovascular disease and neurodegenerative diseases. GLYATL2 has been shown to be involved in the regulation of glucose metabolism by promoting the uptake and storage of glucose in the liver and by suppressing the production of pro-inflammatory cytokines.

GLYATL2 has also been shown to be involved in the regulation of various signaling pathways that are involved in disease development and progression. For example, GLYATL2 has been shown to be involved in the regulation of inflammation by suppressing the production of pro-inflammatory cytokines and promoting the production of anti-inflammatory cytokines. It has also been shown to be involved in the regulation of cell survival and metabolism by regulating cell proliferation and lifespan.

In conclusion, GLYATL2 is a protein that has been shown to play a key role in various physiological processes in the body, including fatty acid oxidation and homeostasis. It is expressed in various tissues and has been shown to be involved in the regulation of fatty acid oxidation, body weight and metabolism, and inflammation. GLYATL2 is a potential drug target and biomarker for various diseases, including obesity, diabetes, and fatty liver disease. Further research is needed to fully understand the role of GLYATL2 in disease and to develop effective treatments.

Protein Name: Glycine-N-acyltransferase Like 2

Functions: Mitochondrial acyltransferase which transfers the acyl group to the N-terminus of glycine (PubMed:22475485, PubMed:20305126). Conjugates numerous substrates, such as arachidonoyl-CoA and saturated medium and long-chain acyl-CoAs ranging from chain-length C8:0-CoA to C18:0-CoA, to form a variety of N-acylglycines. Shows a preference for monounsaturated fatty acid oleoyl-CoA (C18:1-CoA) as an acyl donor. Does not exhibit any activity toward C22:6-CoA and chenodeoxycholoyl-CoA, nor toward serine or alanine (PubMed:20305126)

The "GLYATL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GLYATL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets